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Abstract
Human cytomegalovirus (hCMV) is a highly prevalent pathogen that, upon primary infection, establishes life-long
persistence in all infected individuals. Acute hCMV infections cause a variety of diseases in humans with developmental or
acquired immune deficits. In addition, persistent hCMV infection may contribute to various chronic disease conditions even
in immunologically normal people. The pathogenesis of hCMV disease has been frequently linked to inflammatory host
immune responses triggered by virus-infected cells. Moreover, hCMV infection activates numerous host genes many of
which encode pro-inflammatory proteins. However, little is known about the relative contributions of individual viral gene
products to these changes in cellular transcription. We systematically analyzed the effects of the hCMV 72-kDa immediate-
early 1 (IE1) protein, a major transcriptional activator and antagonist of type I interferon (IFN) signaling, on the human
transcriptome. Following expression under conditions closely mimicking the situation during productive infection, IE1 elicits
a global type II IFN-like host cell response. This response is dominated by the selective up-regulation of immune stimulatory
genes normally controlled by IFN-c and includes the synthesis and secretion of pro-inflammatory chemokines. IE1-mediated
induction of IFN-stimulated genes strictly depends on tyrosine-phosphorylated signal transducer and activator of
transcription 1 (STAT1) and correlates with the nuclear accumulation and sequence-specific binding of STAT1 to IFN-c-
responsive promoters. However, neither synthesis nor secretion of IFN-c or other IFNs seems to be required for the IE1-
dependent effects on cellular gene expression. Our results demonstrate that a single hCMV protein can trigger a pro-
inflammatory host transcriptional response via an unexpected STAT1-dependent but IFN-independent mechanism and
identify IE1 as a candidate determinant of hCMV pathogenicity.
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Introduction
Human cytomegalovirus (hCMV), the prototypical b-herpesvi-
rus, is an extremely widespread pathogen (reviewed in [1]).
Primary hCMV infection is invariably followed by life-long viral
persistence in all infected individuals. The groups most evidently
affected by hCMV disease are humans with acquired or
developmental immune deficits including allograft recipients
receiving immunosuppressive drugs, human immunodeficiency
virus-infected individuals, cancer patients undergoing intensive
chemotherapy, and infants infected in utero (reviewed in [2]). In
immunologically normal hosts, clinically relevant symptoms rarely
accompany acute infections (reviewed in [3]), but viral persistence
may contribute to chronic disease conditions including athero-
sclerosis, cardiovascular disease, inflammatory bowel disease,
immune senescence, and certain malignancies (reviewed in
[4,5,6,7,8]).
The pathogenesis of disease (e.g., pneumonitis, retinitis,
hepatitis, enterocolitis, and encephalitis) associated with acute
hCMV infection in immunocompromised people is most readily
attributable to end organ damage either directly caused by
cytopathic viral replication or by host immunological responses
that target virus-infected cells. In contrast, chronic disease
associated with persistent hCMV infection in immunocompetent
individuals as well as in the allografts of transplant recipients is
most likely related to prolonged inflammation (reviewed in [9]). In
fact, hCMV has been frequently detected in the midst of intense
inflammation, and a myriad of studies from transplant recipients
and normal hosts have presented a strong case for this virus as an
etiologic agent in chronic inflammatory processes, particularly
those resulting in vascular disease (reviewed in [4]). At the
molecular level, this is reflected by the fact that, in both human
cells and animal models, cytomegalovirus infections activate
numerous host genes many of which encode growth factors,
cytokines, chemokines, and adhesion molecules with pro-inflam-
matory and immune stimulatory activities [10,11,12,13,14,
15,16,17,18,19,20,21,22,23]. A number of these virus-induced
proteins are released from infected cells forming the viral
‘‘secretome’’ [4,24,25].
A large proportion of human genes that undergo activation
during hCMV infection are normally controlled by interferons
(IFNs) (reviewed in [26,27]). The IFNs constitute a distinct group
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response to the presence of many different pathogens including
hCMV. They are divided among three classes: type I IFNs
(primarily IFN-a and IFN-b), type II IFN (IFN-c), and type III
IFNs (IFN-l or interleukin 28/29). The type I IFNs share many
biological activities with type III IFNs, especially in host protection
against viruses. IFN-c, the sole type II IFN, is one of the most
important mediators of inflammation and immunity exerting
pleiotropic effects on activation, differentiation, expansion and/or
survival of virtually any cell type of the immune system (reviewed
in [28]). A significant body of research has identified the primary
IFN pathway components and has characterized their roles in
‘‘canonical’’ signaling (reviewed in [29,30]). In this pathway, IFNs
bind to their cognate cell surface receptors to induce conforma-
tional changes that activate the receptor-associated enzymes of the
Janus kinase (JAK) family. The post-translational modifications
that follow this activation create docking sites for proteins of the
signal transducer and activator of transcription (STAT) family
with seven human members. In turn, the STAT proteins undergo
JAK-mediated phosphorylation at a single tyrosine residue (Y701
in STAT1), which triggers their transition to an active dimer
conformation. The STAT dimers accumulate in the nucleus where
they may recruit additional proteins, and these complexes then
bind sequence-specifically to short DNA motifs termed IFN-
stimulated response element (ISRE) or gamma-activated sequence
(GAS). ISREs are usually bound by a ternary complex composed
of a STAT1-STAT2 heterodimer and IFN regulatory factor (IRF)
9, which forms upon induction by type I and type III IFNs and is
referred to as IFN-stimulated gene factor 3 (ISGF3). In contrast,
type II IFN typically signals via STAT1 homodimers that associate
with GAS elements. Finally, promoter-associated STAT proteins
stimulate transcription of numerous IFN-stimulated genes (ISGs)
via their carboxy-terminal transcriptional activation domain.
Within this domain, phosphorylation of a serine residue (S727 in
STAT1) can augment STAT transcriptional activity. To some
extent, the complex responses elicited by type I, type II, and type
III IFNs are redundant as a consequence of partly overlapping
ISGs.
Since many ISGs, especially those induced by type I IFNs,
exhibit potent anti-viral activities most viruses have evolved escape
mechanisms that mitigate IFN responses. In fact, both hCMV and
murine cytomegalovirus (mCMV) are known to disrupt IFN
pathways at multiple points (reviewed in [26,27]). For example,
JAK-STAT signaling is inhibited by the hCMV 72-kDa
immediate-early 1 (IE1) gene product [31,32,33], a key regulatory
nuclear protein required for viral early gene expression and
replication in fibroblasts infected at low input multiplicities
[34,35,36]. IE1 orthologs of mCMV and rat cytomegalovirus
(rCMV) also contribute to replication and virulence in the
respective animals [37,38]. The hCMV IE1 protein counteracts
virus- or type I IFN-induced ISG activation via complex formation
with STAT1 and STAT2 resulting in reduced binding of ISGF3 to
ISREs [31,32,33,39]. STAT2 interaction contributes to hCMV
type I IFN resistance and to IE1 function during productive
infection [33], but the viral protein undergoes many additional
host cell interactions (reviewed in [2,40,41]). For example, IE1
targets subnuclear structures known as promyelocytic leukemia
(PML) bodies or nuclear domain 10 (ND10) ([42,43,44]; reviewed
in [45,46,47,48]). In addition, IE1 associates with chromatin [49]
and interacts with a variety of transcription regulatory proteins
[50,51,52,53,54,55,56,57]. Consequently, IE1 stimulates expres-
sion from a broad range of viral and cellular promoters in transient
transfection assays. However, IE1-mediated activation or repres-
sion of merely a few single endogenous human genes has been
demonstrated so far [58,59,60,61,62,63,64].
Here we present the results of the first systematic human
transcriptome analysis following expression of the hCMV IE1
protein. Surprisingly, the predominant response to IE1 was
characterized by activation of pro-inflammatory and immune
stimulatory genes normally controlled by IFN-c. We further
demonstrate that IE1 employs an unusual mechanism, which does
not require induction of IFNs but nonetheless depends on
activated (Y701-phosphorylated) STAT1, to up-regulate a subset
of ISGs.
Results
Construction and characterization of human primary cells
with inducible IE1 expression
The hCMV IE1 protein exhibits complex activities, and results
obtained from experiments with IE1 mutant virus strains are
inherently difficult to interpret. In fact, regarding the phenotype of
IE1-deficient viruses at low input multiplicities, it seems almost
impossible to discriminate between effects directly linked to any of
the IE1 activities and indirect effects caused by delays in
downstream viral gene expression and replication. On the other
hand, following infection at high multiplicity, many consequences
of absent IE1 expression are compensated for by excess viral
structural components, such as tegument proteins and/or DNA,
and therefore undetectable ([35,36]; reviewed in [2,40,41]). Thus,
it is apparent that cells with inducible expression of functional IE1
at physiological levels would be highly useful by allowing a definite
assessment of the viral protein’s activities outside the confounding
context of infection. Furthermore, such cells would avoid potential
difficulties typically associated with transient transfection, includ-
ing variable frequency of positive cells and protein accumulation
to non-physiologically high levels. Importantly, an inducible
expression system would also preclude cells from adapting to
long-term IE1 expression. In fact, the continued presence of IE1 is
Author Summary
Human cytomegalovirus (hCMV) is a leading cause of birth
defects and severe disease in people with compromised
immunity. Disease caused by hCMV is frequently linked to
inflammation, and the virus has been shown to induce
numerous host genes many of which encode pro-
inflammatory proteins. However, little is known about
the contributions of individual viral proteins to these
changes in cellular transcription. We systematically ana-
lyzed the effects of the hCMV immediate-early 1 (IE1)
protein, a major viral transcriptional activator, on expres-
sion of .28,000 human genes. Following expression under
conditions mimicking the situation during hCMV infection,
IE1 elicited a transcriptional response dominated by the
up-regulation of pro-inflammatory and immune stimula-
tory genes normally induced by the secreted signaling
protein interferon-c. However, IE1-mediated gene expres-
sion was independent of interferon induction, yet required
the activated form of signal transducer and activator of
transcription 1 (STAT1), a central mediator of interferon
signaling. Indeed, STAT1 moved to the nucleus and
became associated with IE1 target genes upon expression
of the viral protein. Our results demonstrate that a single
hCMV protein can trigger a pro-inflammatory host cell
response via an unexpected mechanism and suggest that
IE1 may contribute to hCMV disease in more direct ways
than previously thought.
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proliferation [65,66,67].
We used a tetracycline-dependent induction (Tet-on) system
built into lentivirus vectors to generate cells in which IE1
expression can be synchronously induced and compared to cells
not expressing the viral protein. The first component of this system
is a lentiviral vector (pLKOneo.CMV.EGFPnlsTetR; [68,69,70])
that includes a hybrid gene encoding the tetracycline repressor
(TetR) linked to a nuclear localization signal (NLS) derived from
the SV40 large T antigen and the enhanced green fluorescent
protein (EGFP) to produce an EGFPnlsTetR fusion protein [68].
In addition, this vector encodes neomycin resistance. The second
component is a lentivirus vector (pLKO.DCMV.TetO.cIE1)
conferring puromycin resistance, in which a fragment of the
hCMV promoter-enhancer drives expression of the IE1 (Towne
strain) cDNA. In this vector, tandem tetracycline operator (TetO)
sequences are present immediately downstream of the TATA box.
For the lentivirus transductions, we chose MRC-5 primary human
embryonic lung fibroblasts, because they support robust wild-type
hCMV replication, whereas IE1-deficient virus strains exhibit a
severe growth defect after low multiplicity infection of these cells
([31,33] and Figure 1 C). Initially, low passage MRC-5 cells were
transduced with lentivirus prepared from plasmid pLKOneo.CM-
V.EGFPnlsTetR, and a neomycin-resistant polyclonal cell popu-
lation (named TetR) was isolated in which almost all cells
expressed the EGFP fusion protein located in the nucleus (data
not shown). Next, TetR cells were transduced with lentivirus
prepared from pLKO.DCMV.TetO.cIE1 and a mixed cell
population (named TetR-IE1) exhibiting both neomycin and
puromycin resistance was selected. Finally, fluorescence-activated
cell sorting was performed to collect cells with high levels of
EGFPnlsTetR and, consequently, low levels of IE1 in the absence
of inductor.
To characterize the newly generated cells, TetR-IE1 cells were
treated with doxycycline for 24 or 72 h and examined for IE1
expression by indirect immunofluorescence microscopy (Figure 1
A). Before induction, the majority (67.0%) of cells was IE1
negative, and most other cells expressed barely detectably levels of
the viral protein. Interestingly, in the latter proportion of cells IE1
was present in a predominantly punctate nuclear pattern. This
likely reflects stable co-localization between IE1 and ND10 due to
viral protein levels insufficient to disrupt the nuclear structures. At
24 h following induction only 2.8% of cells were negative for IE1
expression and .97% stained positive for the viral protein. In
almost all positive cells IE1 exhibited a largely diffuse nuclear
staining indicating complete disruption of ND10. Very similar
results were obtained for IE1 expression and localization 72 h post
induction. Importantly, the observed temporal and spatial pattern
of IE1 subnuclear localization in TetR-IE1 cells closely resembles
that observed during productive hCMV infection in fibroblasts
where initial colocalization between IE1 and ND10 is succeeded
by ND10 disruption and diffuse nuclear distribution of the viral
protein [43,44,71].
To compare the relative levels of IE1 expressed during hCMV
infection and after induction of TetR-IE1 cells, TetR cells were
infected with the hCMV Towne strain, and samples collected
before or 3 h, 6 h, 12 h, 24 h, 48 h and 72 h after infection were
analyzed for IE1 steady-state protein levels in comparison with
samples of TetR-IE1 cells that had been treated with doxycycline
(Figure 1 B). The timing of IE1 induction in TetR-IE1 cells was
remarkably similar to the kinetics of IE1 accumulation in hCMV-
infected cells. In addition, the IE1 levels detected at 24 to 72 h
post induction were comparable to the protein amounts that had
accumulated by 24 h post hCMV infection.
To confirm that TetR-IE1 cells express fully active IE1,
replication of wild-type and IE1-deficient hCMV strains was
compared by multi-step analyses conducted in doxycycline-treated
TetR and TetR-IE1 cells (Figure 1 C). To this end, we employed a
bacterial artificial chromosome (BAC)-based recombination ap-
proach to generate a ‘‘markerless’’ mutant virus strain (TNdlIE1)
lacking the entire IE1-specific coding sequence. For details on the
construction of TNdlIE1 and a revertant virus (TNrvIE1) see
Materials and Methods. As expected, the replication of two
independent TNdlIE1 clones was strongly attenuated in TetR
cells, with a ,2t o.3 log difference in titers between mutant and
revertant virus strains. It is important to note that our previous
work has shown that TNrvIE1 and the parental wild-type strain
(TNwt) exhibit identical replication kinetics [33]. However,
induced TetR-IE1 cells were able to support wild-type-like
replication of the TNdlIE1 viruses demonstrating that the viral
protein provided in trans can fully compensate for the lack of IE1
expression from the hCMV genome during productive infection.
Interestingly, even the titers of TNrvIE1 were reproducibly up to
,20-fold higher in TetR-IE1 as compared to IE1-negative cells
between 3 and 12 days post infection.
Taken together, these results show that in TetR-IE1 cells
expression of IE1 can be synchronously induced from the
autologous hCMV major IE (MIE) promoter resulting in fully
functional protein at levels present during the early stages of
hCMV infection. Thus, TetR/TetR-IE1 cells present an ideal
model to study the activities of the IE1 protein outside the
complexity of infection, yet under physiological conditions.
IE1 triggers a pro-inflammatory and immune stimulatory
human transcriptome response
The capacity of hCMV IE1 to activate transcription from both
viral and cellular promoters has long been appreciated ([72];
reviewed in [2,40,41]). However, most reports on IE1-regulated
host gene transcription have relied on transient transfections and
promoter-reporter assays. To our knowledge, regulation of
endogenous cellular transcription by IE1 has so far only been
studied sporadically and at the level of single genes.
To comprehensively assess the impact of IE1 on the human
transcriptome, we performed a systematic gene expression
analysis using our TetR/TetR-IE1 cell model and Affymetrix
GeneChip Human Gene 1.0 ST Arrays covering 28,869 genes
(.99% of sequences currently present in the RefSeq database,
National Center for Biotechnology Information). We compared
the gene expression profiles at 24 h and 72 h post induction in
induced versus non-induced TetR-IE1 cells and in induced TetR-
IE1 versus induced TetR cells. Expression from the vast majority
(99.9%) of genes represented on the arrays was not significantly
affected by IE1. However, mRNA levels of 38 human genes
differed by a factor of two or more (p.0.01) in both the induced
TetR-IE1/non-induced TetR-IE1 and the induced TetR-IE1/
induced TetR comparisons. For 32 (84%) of the 38 genes,
changes in mRNA levels were only observed after 72 h (but not
24 h) of IE1 expression, and only six (16%) were differentially
expressed at both 24 h and 72 h. Moreover, 13 (34%) of these
genes were down-regulated by a factor between 2.0 and 5.5 (data
not shown) and 25 (66%) were up-regulated by a factor between
2.0 and 41.9 (Table 1). For the present work, we concentrated on
the set of genes that was found to be up-regulated by expression
of IE1.
We utilized the Gene Ontology (GO) classification system
(http://www.geneontology.org) to identify attributes which pre-
dominate among IE1-activated gene products regarding the three
GO domains ‘‘biological process’’, ‘‘molecular function’’, and
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tools to construct maps that visualize overrepresented attributes on
the GO hierarchy (Figure 2). According to GO, the most
significantly enriched ‘‘biological process’’ terms with respect to
the 25 IE1-activated genes are: ‘‘immune system process’’,
‘‘immune response’’, ‘‘inflammatory response’’, ‘‘response to
wounding’’, ‘‘response to stimulus’’, ‘‘defense response’’, ‘‘chemo-
taxis’’, ‘‘taxis’’, and ‘‘regulation of cell proliferation’’ (Figure 2 A).
Figure 1. Characterization of TetR-IE1 cells. A) TetR-IE1 cells were
treated with doxycycline for 24 and 72 h or were left untreated (0 h).
Paraformaldehyde-fixed samples were examined by fluorescence
microscopy for IE1 (antibody 1B12) and TetRnlsEGFP (TetR) expression
(autofluorescence). Staining with 49,6-diamidino-2-phenylindole (DAPI)
was performed to visualize nuclei. Original magnification,6504. For the
pie charts, ,500 randomly selected nuclei per sample were examined
for IE1 expression. The scoring system is as follows: IE1 2, no IE1
staining above background; IE1 +, weak, mostly punctate IE1 staining;
IE1 ++, strong, diffuse IE1 staining. B) Time course (0–72 h) immunoblot
analysis of IE1 and GAPDH steady-state protein levels in doxycycline-
induced TetR-IE1 cells and hCMV (TNwt)-infected TetR cells (MOI=1
PFU/cell). To assure comparability between protein bands, gels loaded
with extracts from equal cell numbers were run and blotted side by side
under the same conditions, and pairs of membranes destined for IE1 or
GAPDH detection were processed together and exposed on the same
film. C) Multistep replication analysis of IE1-null mutant hCMV (TNdlIE1)
and the corresponding revertant virus (TNrvIE1) in doxycycline-treated
TetR and TetR-IE1 cells. Confluent cells were infected at an MOI of 0.01
PFU/cell, and viral replication was monitored at 3-day intervals by qPCR-
based relative quantification of hCMV DNA from culture supernatants.
Mean values and standard deviations of four independent infections
with two different clones per each virus strain are shown.
doi:10.1371/journal.ppat.1002016.g001
Table 1. Human genes with increased mRNA levels after IE1
induction.
Gene Maximum fold increase
24 h post induction 72 h post induction
ID Symbol IE1+/TetR+ IE1+/IE12 IE1+/TetR+ IE1+/IE12
8995 TNFSF18 9.0 2.6 12.6 4.8
7292 TNFSF4 6.2 2.1 6.5 2.5
3627 CXCL10 3.5 2.4 41.9 24.6
27063 ANKRD1 3.3 2.3 10.1 8.3
1906 EDN1 2.4 1.9 3.3 3.6
3620 IDO1 1.6 1.1 28.7 20.2
115361 GBP4 1.7 1.2 17.3 13.5
6373 CXCL11 1.4 1.1 13.3 10.5
115362 GBP5 1.1 1.0 7.5 7.0
10964 IFI44L 1.3 1.1 4.6 4.4
4283 CXCL9 1.3 1.0 4.5 4.2
29126 CD274 1.2 1.5 3.9 4.5
3122 HLA-DRA 1.2 1.1 3.4 3.5
2633 GBP1 1.5 1.2 3.1 2.7
3433 IFIT2 1.4 1.0 2.9 2.0
6356 CCL11 1.7 1.2 2.8 2.2
3280 HES1 1.7 1.3 2.6 2.2
56256 SERTAD4 1.4 1.1 2.6 2.0
2634 GBP2 21.1 21.1 2.5 3.9
1520 CTSS 1.0 1.0 2.5 2.2
3047 HBG1 1.2 1.0 2.4 2.1
3659 IRF1 1.2 1.3 2.3 2.5
6890 TAP1 1.2 1.1 2.3 2.1
83643 CCDC3 1.1 1.1 2.3 2.1
3437 IFIT3 21.1 1.9 2.1 2.1
IE1+, doxycycline-treated TetR-IE1 cells; TetR+, doxycycline-treated TetR cells;
IE12, non-induced TetR-IE1 cells.
doi:10.1371/journal.ppat.1002016.t001
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have been implicated in adaptive or innate immune processes
including inflammation. Moreover, 7 (28%) of the 25 genes
encode known cytokines or other soluble mediators, namely the
chemokine (C-X-C motif) ligands CXCL9, CXCL10 and
CXCL11, the chemokine (C-C motif) ligand CCL11, endothelin
1 (encoded by EDN1), and the tumor necrosis factor (TNF)
superfamily members 4 (TNFSF4, also known as OX40 ligand)
and 18 (TNFSF18, also known as GITR ligand). This observation
is also illustrated by the fact that, according to GO, the most
significantly enriched ‘‘molecular function’’ terms in the IE1-
activated transcriptome are: ‘‘cytokine receptor binding’’, ‘‘cyto-
kine activity’’, ‘‘chemokine activity’’, ‘‘chemokine receptor bind-
ing’’, and ‘‘G-protein-coupled receptor binding’’ (Figure 2 B).
Furthermore, the top ‘‘cellular component’’ category is ‘‘extracel-
lular space’’ (Figure 2 C). For a more thorough assessment of
Figure 2. Predominant functional themes among IE1-activated genes. Cytoscape (http://www.cytoscape.org [219,220]) and the Biological
Networks Gene Ontology (BiNGO) plugin (http://www.psb.ugent.be/cbd/papers/BiNGO [221]) were used to map and visualize overrepresented terms
in the IE1-activated human transcriptome on the GO hierarchy. Spatial arrangement of nodes reflects grouping of categories by semantic similarity.
The node area is proportional to the number of genes in the reference set (‘‘GO Full’’, Homo sapiens) annotated to the corresponding GO term. The
yellow to orange node color indicates how significantly individual terms are overrepresented (p#0.01; hypergeometric test including Benjamini and
Hochberg False Discovery Rate correction [222]). White nodes are included to show the colored nodes in the context of the GO hierarchy and are not
significantly overrepresented. Black nodes represent the three GO domains: A) biological process, B) molecular function, and C) cellular component.
doi:10.1371/journal.ppat.1002016.g002
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Supporting Tables S1, S2 and S3.
Surprisingly, the genes induced by IE1 are generally associated
with stimulatory rather than inhibitory effects on immune function
including inflammation (Figure 2 A and Supporting Table S1). For
example, some of the gene products are involved in the proteolysis
(cathepsin S encoded by CTSS), intracellular transport (TAP1
transporter) or cell surface presentation (HLA-DRA) of antigens
(reviewed in [73]). The chemokines CXCL9, CXCL10, and
CXCL11 mediate leukocyte migration (see Discussion; reviewed in
[73,74,75]). CD274 (also known as PDL1), TNFSF4, and
TNFSF18 are co-stimulatory molecules which promote leukocyte
(including T and B lymphocyte) activation, proliferation and/or
survival (reviewed in [73,76,77,78,79]). Indoleamine 2,3-dioxy-
genase 1 (IDO1) and IRF1 have also been linked to T lymphocyte
regulation, but they have additional functions in innate immune
control of viral infection (reviewed in [73,80,81,82,83,84,85].
Likewise, GBP1 and murine GBP2 exhibit antiviral activity
[86,87,88,89].
Out of the 25 IE1-activated genes, 14 were selected for
validation by qRT-PCR. The selected genes were representative of
the entire range of expression kinetics and induction magnitudes
measured by microarray analysis. The PCR approach confirmed
expression of all tested genes typically reporting similar or larger
fold increases compared to the array data (Figure 3 A–B and
Figure 4 A). For example, in induced (72 h) versus non-induced
TetR-IE1 cells the CXCL10 mRNA was found to be increased
24.6-fold by array analysis (Table 1) and 68.0-fold by PCR
(Figure 3 A). Under the same conditions, the GBP4 transcript was
induced 13.5-fold by array analysis (Table 1) as compared to 19.1-
fold by PCR (Figure 3 A). The corresponding data for TAP1 were
2.1-fold (array analysis; Table 1) and 2.3-fold (PCR; Figure 3 A).
Largely concordant results regarding induction magnitudes
between array and PCR analyses were also obtained for CCDC3,
CCL11, HES1, SERTAD4, TNFSF4, and TNFSF18 (Figure 3 B)
as well as for CXCL9, CXCL11, IDO1, IFIT2, and IRF1
(Figure 4 A). In addition to the extent of gene activation, the
precise timing of induction was exemplary investigated for
CXCL10, GBP4 and TAP1 (Figure 3 A). A substantial increase
in mRNA production from all three genes was evident at 72 h
(and to a lesser extent at 48 h) but only minor effects were detected
between 6 h and 24 h post IE1 induction consistent with the array
data (Table 1). Tubulin-b (TUBB) gene expression, which is not
affected by IE1, served as a negative control for the PCR
experiments. Finally, the chemokines CXCL9 and CXCL11 were
exclusively detected in supernatants from TetR-IE1 but not TetR
cells (Figure 3 C). Moreover, the levels of CXCL10 protein were
drastically increased in TetR-IE1 compared to TetR cells. This
demonstrates that for these genes elevated mRNA levels also
translate into enhanced protein synthesis and secretion.
The fact that increased expression of all tested IE1-activated
genes was detectable with two or three alternative approaches
strongly suggests that essentially all genes identified within the
given experimental framework and data analysis settings are truly
differentially expressed upon induction of IE1. Moreover, the
activation of at least a subset of IE1-responsive genes appears to be
temporally coupled.
Most IE1-activated genes are ISGs normally controlled by
IFN-c
A plethora of past studies has established that immune
regulatory genes are preferential targets of IFN-based regulation
[28,29,30]. Intriguingly, at least 21 (84%) of the 25 IE1-activated
human genes identified by microarray analysis turned out to be
bona fide ISGs (Table 2) according to informations retrieved from
the Interferome database (http://www.interferome.org [90]) and
other sources including our own qRT-PCR analyses (Figure 4 A
and Supporting Table S4). Several of these ISGs cluster in certain
chromosomal locations (e.g., 1p22, 4q21, and 10q23-q25; Table 2)
apparently reflective of their co-regulation.
Figure 3. Confirmation of IE1-induced gene expression. A) TetR
and TetR-IE1 cells were treated with doxycycline for 0 to 72 h as
indicated. Relative mRNA expression levels were determined by qRT-
PCR with primers specific for the CXCL10, GBP4, TAP1, and TUBB genes.
Means and standard deviations of two replicates are shown in
comparison to uninduced TetR-IE1 cells (set to 1). B) TetR and TetR-
IE1 cells were treated with doxycycline for 72 h. Relative mRNA
expression levels were determined by qRT-PCR with primers specific for
the indicated genes. Means and standard deviations of two biological
and two technical replicates are shown in comparison to TetR cells (set
to 1). C) Quantification of the CXCR3 ligands CXCL9, CXCL10, and
CXCL11 in the supernatant of IE1 expressing cells. Growth-arrested TetR
and TetR-IE1 cells were treated with doxycycline for 72 h. The culture
medium was replaced by 0.5 volumes of doxycycline containing DMEM
with 0.1% BSA, and chemokine protein accumulation was determined
24 h later by quantitative sandwich enzyme immunoassay. Means and
standard deviations of two biological and two technical replicates are
shown.
doi:10.1371/journal.ppat.1002016.g003
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revealed that IE1-activated ISGs are normally induced by either
only IFN-c or by both type II and type I IFNs (Table 2). To
confirm this assignment and to further discriminate between type I
and type II ISGs, we treated TetR and TetR-IE1 cells with
exogenous IFN-a or IFN-c and analyzed the effects on mRNA
accumulation from a select subset of IE1-responsive ISGs. The
transcript levels of all tested ISGs, namely CXCL9–11, GBP4,
IDO1, IFIT2, IRF1, and TAP1 (Figure 4 A) as well as CCL11
(Supporting Table S4) were not only increased by IE1 expression
(TetR-IE1 relative to TetR cells) but also by IFN-c treatment of
TetR cells, although to varying degrees (,2t o.30,000-fold;
Figure 4 A). Notably, there was a significant positive correlation
(Pearson’s correlation coefficient=0.81) between the magnitudes
of IE1- and IFN-c-mediated ISG induction. In contrast, the same
genes were substantially less susceptible (CXCL9–11, GBP4,
IDO1, and IFIT2) or entirely unresponsive (CCL11, IRF1, and
TAP1) to IFN-a (Figure 4 A), and there was no correlation
(Pearson’s correlation coefficient=20.04) between IE1 and IFN-a
responsiveness. For comparison, three typical type I ISGs, the
genes encoding eukaryotic translation initiation factor 2a kinase 2
(EIF2AK2, also known as PKR), myxovirus (influenza virus)
resistance 1 (Mx1, also known as MxA), and 29,59-oligoadenylate
synthetase (OAS1), were strongly induced by IFN-a but barely by
IFN-c or IE1 (Figure 4 B). Although no obvious synergistic or
additive effects between IE1 expression and IFN-c treatment were
observed in these assays (Figure 4 A–B), IFN-a induction of type I
ISGs was severely compromised in TetR-IE1 as compared to
TetR cells (Figure 4 B). The latter observation is consistent with
our previous work which has demonstrated that IE1 blocks
STAT2-dependent signaling resulting in inhibition of type I ISG
activation [31,33].
Hence, it appears that expression of IE1 selectively activates a
subset of ISGs and ISG gene clusters which are primarily
responsive to IFN-c indicating that the viral protein elicits a type
II IFN-like transcriptional response.
IE1-mediated ISG activation is independent of IFNs
ISG activation typically requires synthesis, secretion and
receptor binding of IFNs (reviewed in [26,27,29,30]). IFN-a is
encoded by a multi-gene family and is mainly expressed in
leukocytes although some members are stimulated by IFN-b in
fibroblasts [91]. However, neither of 12 IFN-a (IFNA) and three
alternative type I IFN coding genes (IFNE, IFNK, and IFNW1
Figure 4. IE1 induces an IFN-c-like transcriptional response. TetR and TetR-IE1 cells were treated with doxycycline for 72 h and solvent (w/o),
IFN-a, or IFN-c for 24 h. Relative mRNA expression levels were determined by qRT-PCR with primers specific for a set of IE1-responsive genes (A),
typical type I IFN response genes and IE1 itself (B). Results were normalized to TUBB, and mean values with standard deviations from two biological
and two technical replicates are shown. ISG expression is shown in comparison to untreated TetR cells (set to 1). IE1 expression is presented relative
to untreated TetR-IE1 cells (set to 1).
doi:10.1371/journal.ppat.1002016.g004
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induced by IE1 as judged by our microarray results (Supporting
Table S5). In contrast to IFN-a, IFN-b is encoded by a single gene
(IFNB) and is produced by most cell types, especially by fibroblasts
(IFN-b is also known as ‘‘fibroblast IFN’’). However, previous
work has shown that IE1 expression does not induce transcription
from the IFN-b gene in fibroblasts [31,32,92]. Consistently, our
microarray data did not reveal appreciable differences in IFNB1
mRNA levels between TetR and TetR-IE1 cells (Supporting
Table S5). The single human IFN-c gene (IFNG) is expressed
upon stimulation of many immune cell types but not usually in
fibroblasts, and our microarray results indicate that IE1 does not
activate expression from this gene. Likewise, none of the known
type III IFN genes (IL28A, IL28B, and IL29 encoding IFN-l2/IL-
28A, IFN-l3/IL-28B, and IFN-l1/IL-29, respectively) was
significantly responsive to IE1 expression in this system (Support-
ing Table S5). For the IFN-b and IFN-c transcripts, these results
were confirmed by highly sensitive qRT-PCR from doxycycline-
treated TetR-IE1 and TetR cells. Levels of the two IFN mRNAs
did not significantly differ between TetR-IE1 and TetR cells at
any of ten post induction time points (0 h–96 h) under
investigation (Supporting Figure S1 and Supporting Table S6).
Thus, IE1 does not seem to induce expression from the IFN-c or
any other human IFN gene.
To further rule out the possibility that ISG activation is a result
of low level IFN production or secretion of any other soluble
mediator from IE1 expressing cells, culture supernatants from
TetR-IE1 cells induced with doxycycline for 24 h or 72 h were
transferred to MRC-5 cells. As expected, MRC-5 cells did not
undergo ISG induction 3 h to 72 h following media transfer (data
not shown). Furthermore, we set up a transwell system with TetR
cells in the top and TetR-IE1 cells in the bottom chamber
(Figure 5). Following addition of IFN-c to the lower chamber, we
observed substantially increased mRNA levels of three IE1-
responsive indicator ISGs (CXCL9, CXCL11, and GBP4) in both
TetR and TetR-IE1 cells (Figure 5 A). In contrast, addition of
doxycycline caused up-regulation of ISG mRNA levels in TetR-
IE1 but not TetR cells (Figure 5 B). These results indicate that ISG
induction is restricted to IE1 expressing cells and that a diffusible
factor is not sufficient to mediate gene activation by the viral
protein.
Finally, we performed experiments adding neutralizing anti-
bodies directed against IFN-b and IFN-c to the cell culture media
(Figure 6). ISG-specific qRT-PCRs from TetR cells treated with a
combination of antibodies and high doses of the respective
exogenous IFN confirmed that cytokine neutralization was both
highly effective and specific. At the same time, neither the IFN-b-
nor the IFN-c-specific neutralizing antibodies had any significant
negative effect on IE1-mediated ISG induction. These results
strongly support the view that ISG activation by IE1 is
independent of IFN-b, IFN-c, and likely other IFNs.
IE1-mediated ISG activation depends on STAT1 but not
STAT2
Homodimeric STAT1 complexes are the central intracellular
mediators of canonical IFN-c signaling (reviewed in
[26,27,28,29,30]). Interestingly, previous work has shown that
the IE1 protein interacts with both STAT1 and STAT2, although
STAT2 binding appeared to be more efficient [31,32,33,39].
STAT2 has also been implicated in certain IFN-c responses
([93,94]; reviewed in [95]), although some (hCMV-mediated)
activation of ISG transcription appears to occur entirely
independent of STAT proteins ([96]; reviewed in [26,27]).
To investigate whether ISG activation by IE1 requires the
presence of STAT1 and/or STAT2, we employed siRNA-based
gene silencing individually targeting the two STAT transcripts.
Following transfection of MRC-5, TetR and/or TetR-IE1 cells
Table 2. Genomic location and IFN responsiveness of IE1-
induced human genes.
Gene IFN-responsive
Symbol Locus Yes/No Type Reference
IFI44L 1p31.1 Yes I, II, III Interferome
1
GBP1 1p22.2 Yes I, II, III Interferome
GBP2 1p22.2 Yes I, II Interferome
GBP4 1p22.2 Yes I, II Interferome
II Figure 4 A
GBP5 1p22.2 Yes I, III Interferome
II [223]
CTSS 1q21 Yes I Interferome
II [148]
TNFSF18 1q23 Yes II Interferome
2
2 Supporting Table S4
TNFSF4 1q25 No 2 Interferome
2
2 Supporting Table S4
SERTAD4 1q32.1-q41 No 2 Interferome
2 Supporting Table S4
HES1 3q28-29 Yes 2 Interferome
II Supporting Table S4
CXCL9 4q21 Yes I, II Interferome
I, II Figure 4 A
CXCL10 4q21 Yes II Interferome
I, II Figure 4 A
CXCL11 4q21.2 Yes I, II Interferome
I, II Figure 4 A
IRF1 5q31.1 Yes I, II, III Interferome
II Figure 4 A
EDN1 6p24.1 Yes II Interferome
HLA-DRA 6p21.3 Yes I, II Interferome
TAP1 6p21.3 Yes I, II, III Interferome
II Figure 4 A
IDO1 8p12-11 Yes I, II Interferome
I, II Figure 4 A
CD274 9p24 Yes II Interferome
CCDC3 10p13 No 2 Interferome
2 Supporting Table S4
IFIT2 10q23-q25 Yes I, II, III Interferome
I, II Figure 4 A
IFIT3 10q24 Yes I, II, III Interferome
ANKRD1 10q23.31 Yes I, II Interferome
HBG1 11p15.5 No 2 Interferome
2 Supporting Table S4
CCL11 17q21.1-21.2 Yes 2 Interferome
II Supporting Table S4
1[90].
2Marginally ($1,5-fold) induced by IFN-a and/or IFN-c (Supporting Table S4).
doi:10.1371/journal.ppat.1002016.t002
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we monitored endogenous STAT expression by immunoblotting
(Figure 7 A) and qRT-PCR (Figure 7 B). An estimated $80%
selective reduction in STAT1 and STAT2 protein accumulation
was observed 2 days following siRNA transfection, and even after
5 days significantly lower protein levels were detected compared to
cells transfected with a non-specific control siRNA (Figure 7 A).
The knock-down of STAT1 and STAT2 was also evident at the
level of mRNA accumulation (86 to 95% for STAT1 and 51 to
95% for STAT2 at day 5 post transfection; Figure 7 B). The
knock-down specificity was verified by confirming that STAT1
siRNAs do not significantly reduce STAT2 mRNA levels and vice
versa. Moreover, none of the STAT-directed siRNAs had any
appreciable effect on IE1 expression (Figure 7 B). Again,
expression from the CXCL10 and GBP4 genes was strongly up-
regulated in doxycycline-treated TetR-IE1 versus TetR cells.
However, STAT1 knock-down caused the CXCL10 and GBP4
genes to become almost entirely resistant to IE1-mediated
activation in induced TetR-IE1 cells. In contrast, depletion of
STAT2 had no negative effect on IE1-dependent ISG induction
(Figure 7 B) although it diminished basal and IFN-a-induced type
I ISG (OAS1) expression (Supporting Figure S2). These results
demonstrate that STAT1, but not STAT2, is an essential mediator
of the cellular transcriptional response to IE1 expression and
suggest that the viral protein might mediate ISG activation via
activation of JAK-STAT signaling.
IE1-mediated ISG activation requires STAT1 tyrosine
phosphorylation
The activation-inactivation cycle of STAT transcription factors
entails their transition between different dimer conformations.
Unphosphorylated STATs can dimerize in an anti-parallel
conformation, whereas tyrosine (Y701) phosphorylation triggers
transition to a parallel dimer conformation resulting in increased
DNA binding and nuclear retention of STAT1 (reviewed in
[29,30,97]). In addition, serine (S727) phosphorylation is required
for the full transcriptional and biological activity of STAT1 [98].
In order to investigate whether IE1 promotes STAT1 activation,
we compared the levels of Y701- and S727-phosphorylated
STAT1 in doxycyline-induced TetR and TetR-IE1 cells
(Figure 8 A). Total STAT1 steady-state protein levels were very
similar in TetR and TetR-IE1 cells. In contrast, Y701-phosphor-
ylated forms of STAT1 were only detectable in the presence of IE1
unless cells were treated with IFN-c. In addition, IE1 was almost
as efficient as IFN-c in inducing STAT1 S727 phosphorylation.
These results strongly suggest that IE1 expression triggers the
formation of Y701- and S727-phosphorylated, transcriptionally
fully active STAT1 dimers.
To examine whether STAT1 Y701 and/or S727 phosphory-
lation is an essential step in IE1-mediated ISG activation, we set
up a ‘‘knock-down/knock-in’’ system designed to study mutant
STAT1 proteins in a context of diminished endogenous wild-type
protein levels. We constructed an ‘‘siRNA-resistant’’ STAT1
coding sequence, termed STAT1*, containing two silent nucleo-
tide exchanges in the sequence corresponding to siRNA STAT1
#146 (Figure 7 A). The STAT1* sequence was used as a substrate
for further mutagenesis to generate siRNA-resistant constructs
encoding mutant STAT1 proteins with conservative amino acid
substitutions that preclude tyrosine or serine phosphorylation (Y701F
or S727A, respectively; reviewed in [99,100]). A retroviral gene
transfer system based on vector pLHCX was utilized to efficiently
express the different STAT1 proteins in TetR-IE1 cells. All STAT1
variants (STAT1*, STAT1*Y701F, and STAT1*S727A) were
overexpressed to levels undiscernible from the wild-type protein
Figure 5. ISG induction is limited to IE1 expressing cells. TetR and TetR-IE1 cells were placed in the upper and lower chambers, respectively, of
transwell dishes. Cells were growth-arrested and then treated in one of two ways. A) TetR-IE1 cells in the bottom chambers were treated with IFN-c
for 24 h or were left untreated (w/o). B) TetR cells in the upper and TetR-IE1 cells in the lower chambers were treated with doxycycline (Doxy) for 72 h
or were left untreated (w/o). RNA was prepared from each compartment and analyzed by qRT-PCR with primers for the CXCL9, CXCL11, GBP4, and IE1
genes. Results were normalized to TUBB and mean values with standard deviations from two biological and two technical replicates are shown in
comparison to untreated TetR-IE1 cells (set to 1).
doi:10.1371/journal.ppat.1002016.g005
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non-specific control siRNA (#149), siRNA #146 severely reduced
the levels of endogenous and overexpressed wild-type STAT1
without negatively affecting expression of the siRNA-resistant
STAT1 variants or IE1 (Figure 8 B–C). As expected, the Y701F
and S727A mutant STAT1 proteins did not undergo tyrosine or
serine phosphorylation, respectively, upon stimulation by IFN-c.
Interestingly, while the S727A protein could still be tyrosine-
phosphorylated, the Y701F mutant was defective for both tyrosine
and serine phosphorylation (Figure 8 B). This observation is in
agreement with previous findings showing that IFN-c-dependent
S727 phosphorylation occurs exclusively on Y701-phosphorylated
STAT1 [101]. Ectopic expression of wild-type STAT1, STAT1*,
and STAT1*S727A but not STAT1*Y701F in addition to the
endogenous protein enhanced IE1-mediated activation of CXCL10
and GBP4 transcription. Conversely, siRNA-mediated depletion of
endogenous STAT1 strongly reduced this response. Importantly,
expression of STAT1* in cells depleted of endogenous STAT1
rescued ISG induction by IE1 almost completely. STAT1*S727A
expression also compensated for the lack of endogenous STAT1,
although slightly less efficiently compared to STAT1*, whereas
STAT1*Y701F was unable to rescue IE1-mediated ISG activation
(Figure 8 C).
Thus, although IE1 appears to trigger phosphorylation of
STAT1 at both Y701 and S727, only the former modification is
required for ISG activation. Nonetheless, STAT1 S727 phosphor-
ylation may augment IE1-dependent gene activation.
IE1 facilitates STAT1 nuclear accumulation and promoter
binding
Y701 phosphorylation usually causes a cytoplasmic to nuclear
shift in steady-state localization and efficient sequence-specific
DNA binding of STAT1 dimers (reviewed in [29,30,97]).
Accordingly, immunofluorescence microscopy revealed that the
presence of IE1 strongly promotes nuclear accumulation of
STAT1, very similar to what was observed following addition of
IFN-c (Figure 9 A). In contrast, significant amounts of nuclear
STAT2 were only detected after treatment of cells with IFN-a but
not upon IE1 expression. These results were confirmed by nucleo-
cytoplasmic cell fractionation (Figure 9 B). In these assays, IE1
induction for 72 h was as efficient in promoting STAT1 nuclear
accumulation as treatment with type I or type II IFNs for 1 h. IFN
treatment also strongly induced the nuclear accumulation of
STAT2. However, the levels of nuclear STAT2 increased only
marginally upon expression of IE1.
Finally, we asked whether IE1 may direct STAT1 to promoters
of type II ISGs. Chromatin immunoprecipitation (ChIP) analyses
demonstrated that the viral protein potentiates the recruitment of
STAT1 to certain IFN-c- and IE1-responsive ISG promoters (e.g.,
TAP1) but not to promoters of several non-ISGs (e.g., GAPDH;
Figure 10 A). Moreover, there was a positive correlation between
the magnitude of STAT1 chromatin association induced by IE1
and IFN-c. At the same time, IE1 had no effect on association of
STAT2 with these promoters (Figure 10 B). These results are in
agreement with the fact that a previous global ChIP-sequencing
study has experimentally demonstrated STAT1 association with
14 (56%) out of the 25 IE1-responsive gene promoters identified in
this study ([102] and Supporting Table S7). In addition, 22 (88%)
of these promoter sequences (all except EDN1, HBG1, and HLA-
DRA) carry one or more (up to six) predicted STAT1b binding
sites (GAS elements) according to the PROMO tool (version 3.0.2,
default settings with 15% maximum matrix dissimilarity rate,
http://alggen.lsi.upc.es), which predicts transcription factor bind-
ing sites as defined by position weight matrices derived from the
TRANSFAC (version 8.3) database [103,104]. Similar results were
obtained with other in silico promoter analysis tools (data not
shown).
Based on these findings we propose that IE1 activates a subset of
ISGs at least in part through increasing the nuclear concentration
and sequence-specific DNA binding of phosphorylated STAT1
thereby modulating host gene expression in an unanticipated
fashion.
Discussion
The transcriptional transactivation capacity of the hCMV MIE
proteins has been recognized for decades ([72]; reviewed in
[2,40,41]). For example, it has long been established that the 72-
kDa IE1 protein can stimulate transcription from its own
promoter-enhancer [36,105,106]. IE1 also activates at least a
subset of hCMV early promoters therein collaborating with the
viral 86-kDa IE2 protein [34,35,53,71,72,107,108,109]. Further-
more, IE1 or combinations of IE1 and IE2 can stimulate
expression from a variety of non-hCMV promoters. In fact,
numerous heterologous viral and cellular promoters are responsive
to IE1 or combinations of IE1 and IE2 [50,51,52,57,60,61,71,72,
110,111,112,113,114,115,116,117]. IE1 may accomplish tran-
scriptional activation via interactions with a diverse set of cellular
transcription regulatory proteins thereby acting through multiple
Figure 6. Presence of IFN-b- and IFN-c-neutralizing antibodies
does not impair ISG induction by IE1. TetR and TetR-IE1 cells were
treated with doxycycline for 72 h and with solvent (w/o), IFN-b or IFN-c
for 24 h. Doxycycline and IFN treatment was performed in the
continuous presence of normal goat immunoglobulin G (IgG), goat
anti-IFN-b or goat anti-IFN-c antibodies. Relative mRNA expression
levels were determined by qRT-PCR with primers specific for the
CXCL10, CXCL11, GBP4, and IE1 genes. Results were normalized to TUBB
and mean values with standard deviations from two biological and two
technical replicates are shown. Expression is shown in comparison to
normal IgG-treated cells (set to 1).
doi:10.1371/journal.ppat.1002016.g006
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112,113,117,118,119,120,121,122,123,124,125,126] as well as
epigenetic mechanisms including histone acetylation [53,59,127].
More recently, IE1 has also been implicated in transcriptional
repression [31,32,33,57,62,63,64]. Our own work ([31] and this
study, Figure 4 B) and a report by Huh et al. (2008) has
demonstrated that IE1 can inhibit the hCMV- or IFN-a/b-
dependent activation of human ISGs including ISG54, MxA,
PKR, and CXCL10. The mechanism of inhibition appears to
involve physical interactions of IE1 with the cellular STAT1 and
STAT2 proteins that result in diminished DNA binding of the
ternary ISGF3 complex to promoters of type I ISGs ultimately
interfering with transcriptional activation [31,32,33]. Despite this
plethora of studies, our understanding of the true transcriptional
regulatory capacity of IE1 is still limited. This is mainly due to the
fact that IE1-regulated transcription has almost exclusively been
studied at the single gene level. Moreover, much of the past work
has relied on transfection-based promoter-reporter assays, and
Figure 7. ISG induction by IE1 is dependent on STAT1 but not STAT2. A) Specific reduction in STAT1 (left) and STAT2 (right) protein levels by
siRNA-mediated gene silencing. MRC-5 cells were transfected with the indicated siRNA duplexes. Two and five days post transfection, whole cell
protein extracts were prepared and subjected to immunoblotting with anti-STAT1a, anti-STAT2, and anti-GAPDH antibodies. B) STAT1 (left) but not
STAT2 (right) knock-down abolishes IE1-mediated ISG induction. TetR and TetR-IE1 cells were transfected with the indicated siRNA duplexes. Two
days post transfection, cells were treated with doxycycline for 72 h. Relative mRNA expression levels were determined by qRT-PCR with primers
specific for the CXCL10, GBP4, IE1, STAT1, and STAT2 genes. Results were normalized to TUBB and mean values with standard deviations from two
biological and two technical replicates are shown. CXCL10, GBP4, STAT1, and STAT2 expression is shown in comparison to control siRNA-transfected
TetR cells (set to 1). IE1 expression is presented relative to control siRNA-transfected TetR-IE1 cells (set to 1).
doi:10.1371/journal.ppat.1002016.g007
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enous human genes has been demonstrated so far.
The present work constitutes the first systematic analysis of IE1-
specific changes to transcription from the human genome.
Importantly, to minimize cellular compensatory effects and to
closely mimic the situation during hCMV infection, all experiments
were based on short-term (up to 72 h) induction of IE1 expression
from its autologous promoter (Figure 1 A–B). Just over 0.1% (25 out
of28,869)ofallhumantranscriptsunderexaminationwerefoundto
be significantly up-regulated by IE1 under stringent analysis
conditions (Table 1). This figure may be unexpected in the light
of the reported interactions of IE1 with several ubiquitous
transcription factors and its reputation as a ‘‘promiscuous’’
transactivator. However, rather than causing a broad transcrip-
tional host response, IE1-specific gene activation was largely
restricted to a subset of ISGs that are primarily responsive to
IFN-c (Table 2, Figure 4 and Supporting Table S4). Thus, IE1
appears to activate certain ISGs (typically type II ISGs) while
simultaneously inhibiting the activation of other ISGs (typically type
I ISGs). Importantly, more than half (at least 14 out of the 25) IE1-
activated genes identified in this study were previously shown to be
induced during hCMV infection of fibroblasts and/or other human
cell types (Table 3). This strongly suggests that many if not all IE1-
specific transcriptional changes observed in our expression model
may be relevant to viral infection. On the other hand, our
preliminary results indicate that the conditional replication defect of
IE1 knock-out viruses in human fibroblasts [35,36] may not result
from an inability to initiate an IFN-c-like response (data not shown).
In fact, additional viral gene products are known or expected to
contribute to ISG activation during hCMV infection (reviewed in
[26,27]) and may compensate for IE1 in this respect, at least during
productive infection of fibroblasts.
In addition to being distinctively responsive to IFN-c, most IE1-
activated genes appear to share similar kinetics of induction
Figure 8. ISG induction by IE1 depends on STAT1 tyrosine phosphorylation. A) IE1 expression leads to increased steady-state levels of
Y701- and S727-phosphorylated STAT1. TetR and TetR-IE1 cells were treated for 72 h with doxycycline and for 1 h with solvent (–) or IFN-c. Whole cell
protein extracts were prepared and subjected to immunoblotting with anti-STAT1, anti-pSTAT1 (Y701), anti-pSTAT1 (S727), anti-GAPDH, and anti-IE1
antibodies. B) Verification of knock-down resistance and phosphorylation deficiency of STAT1 variants. TetR-IE1 cells without (–) and with stable
expression of ectopic wild-type STAT1 (STAT1), siRNA-resistant wild-type STAT1 (STAT1*), and siRNA-resistant phosphorylation-deficient STAT1
(STAT1*Y701F and STAT1*S727A) were transfected with negative control (#149) or STAT1-specific (#146) siRNA duplexes. Two days post transfection
cells were treated for 1 h with IFN-c. Whole cell protein extracts were prepared and subjected to immunoblotting with anti-STAT1, anti-pSTAT1
(Y701), anti-pSTAT1 (S727), and anti-GAPDH antibodies. C) Ectopic wild-type STAT1 but not phosphorylation-deficient STAT1 mutants efficiently
rescue IE1-dependent ISG induction in cells depleted of endogenous STAT1. TetR-IE1 cells without (–) and with stable expression of the indicated
ectopic STAT1s were transfected with control (#149) or STAT1-specific (#146) siRNA duplexes. Two days post transfection cells were treated for 72 h
with doxycycline. Relative mRNA expression levels were determined by qRT-PCR with primers specific for the CXCL10, GBP4, IE1, and STAT1 genes.
Results were normalized to TUBB and mean values with standard deviations from two biological and two technical replicates are shown. Expression is
shown in comparison to control siRNA-transfected TetR-IE1 cells without ectopic STAT1 expression (set to 1).
doi:10.1371/journal.ppat.1002016.g008
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locations (Table 2) suggesting a common underlying mechanism of
activation. Specific siRNA-mediated STAT1 (but not STAT2)
knock-down inhibited IE1-dependent activation of several target
ISGs almost completely (Figure 7 A). Conversely, STAT1
overexpression proved to enhance ISG activation in IE1
expressing cells (Figure 8 C). Moreover, defective IE1-activated
ISG transcription in cells depleted of endogenous STAT1 was
efficiently rescued by ectopic STAT1 expression (Figure 8 C).
These results demonstrate that the STAT1 protein is a critical
mediator of the cellular transcriptional response to IE1. Moreover,
this response appears to strictly depend on the Y701-phosphor-
ylated form of STAT1 which is induced by IE1 expression
(Figure 8). Although recent work has shown that some STAT1
functions are executed by the non-phosphorylated protein
(reviewed in [97,99,100]), it is the Y701-phosphorylated form that
preferentially accumulates in the nucleus and binds to DNA with
high affinity (reviewed in [29,30]) providing a mechanism for IE1-
dependent ISG activation. IE1 also induces S727 phosphorylation
of STAT1 (Figure 8 A), but this modification is dispensable merely
serving an augmenting function in ISG activation triggered by the
viral protein (Figure 8 C). Phosphorylation of S727 is thought to be
required for the full transcriptional activity of STAT1 by
recruiting histone acetyltransferase activity [98,128,129]. Interest-
ingly, the hCMV IE1 protein can promote histone acetylation [53]
suggesting it might compensate for S727 phosphorylation by
binding to DNA-associated STAT1.
Our prior work has shown that IE1 physically interacts with
STAT1 during hCMV infection and in vitro, and the two proteins
co-localize in the nuclei of transfected cells treated with IFN-a
[31]. The results of Figure 9 extend these observations by
demonstrating that the viral protein facilitates nuclear accumula-
tion and DNA binding of STAT1 in the absence of IFNs. The
STATs were initially described as cytoplasmic proteins that enter
the nucleus only in the presence of cytokines. However, it has now
been established that STATs constantly shuttle between nucleus
Figure 9. IE1 expression leads to nuclear accumulation of STAT1. A) TetR and TetR-IE1 cells were treated with doxycycline for 72 h. Where
indicated, TetR cells were incubated in the presence of IFN-c or IFN-a for 1 h before samples were fixed with paraformaldehyde and examined by
indirect immunofluorescence coupled to confocal microscopy. Samples were simultaneously reacted with rabbit polyclonal antibodies against STAT1
(left) or STAT2 (right) and a mouse monoclonal antibody against IE1, followed by incubation with a rabbit-specific Alexa Fluor 546 conjugate and a
mouse-specific Alexa Fluor 633 conjugate. TetRnlsEGFP (TetR) fluorescence is shown to visualize nuclei. Additionally, merge images of STAT, IE1, and
TetR signals are presented. Scale bar, 10 mm. B) TetR-IE1 cells were treated with doxycycline for 0 h, 24 h, or 72 h. Cytoplasmic and nuclear extracts
were prepared and subjected to immunoblotting with anti-STAT1, anti-STAT2, anti-GAPDH, anti-H2A, and anti-IE1 antibodies. For the right panel,
TetR-IE1 cells were treated with IFN-a or IFN-c for 1 h before fractionation.
doi:10.1371/journal.ppat.1002016.g009
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[97,130,131]). Thus, complex formation between nuclear resident
IE1 and STAT1 passing through the nucleus may be sufficient to
impair STAT1 export to the cytoplasm resulting in nuclear
retention and increased DNA binding of the cellular protein. In
this scenario, IE1 may increase the levels of Y701-phosphorylated
STAT1 by interfering with nuclear dephosphorylation of the
cellular protein. In fact, DNA binding was shown to protect
STAT1 from dephosphorylation, which normally occurs at a step
preceding export to the cytoplasm [132,133]. This one-step
‘‘nuclear shortcut’’ model assumes that small amounts of Y701-
phosphorylated STAT1 enter the nucleus in the absence of IFNs
and any potential IE1-induced mediators of STAT1 activation.
Conceivably, human fibroblasts (TetR cells) may constitutively
release small amounts of soluble inducers (e.g., certain growth
factors; see below) that maintain residual levels of activated
STAT1 undetectable by immunoblotting (Figure 8 A). Moreover,
we cannot rule out that the fetal calf serum used for cell culture
media may contain factors causing a limited number of STAT1
molecules to undergo Y701 phosphorylation. In contrast,
increased S727 phosphorylation in the presence of IE1 may result
from higher levels of DNA-targeted STAT1, as this modification is
preferentially or exclusively incorporated into the nuclear
chromatin-associated cellular protein, at least during the normal
IFN-c response [101].
Alternatively, IE1 may actively induce STAT1 Y701 phosphor-
ylation thereby promoting nuclear import of STAT1 dimers. This
phosphorylation event is typically mediated by cytoplasmic JAK
family kinases upon ligand-mediated activation of IFN receptors.
However, our results demonstrate that IE1 does not induce the
expression of human IFN genes, and we found no evidence for
IFN-c or IFN-b secretion from IE1 expressing cells (Supporting
Table S5, Figure 6 and data not shown). Moreover, our transwell
and media transfer experiments indicate that cytokines or other
soluble mediators that may constitute a hypothetical IE1
‘‘secretome’’ are not sufficient to stimulate ISG expression
(Figure 5 and data not shown). However, this does not rule out
the possibility that IE1 may cooperate with one or more soluble
factors to trigger the observed transcriptional response. In fact,
80% of all IE1 target genes were not found activated within the
first 24 h after induction of IE1 expression despite the fact that the
viral protein had reached almost peak levels by this time (Figure 1
B and Table 1). Instead, up-regulation typically started at 48 h and
increased until at least 72 h following IE1 expression (Table 1 and
Figure 3 A). This timing of induction is compatible with a two-step
model in which IE1 first initiates de novo synthesis and secretion of
an unidentified cellular gene product required to trigger STAT1
Y701 phosphorylation (step 1). Besides IFNs, STAT1 signaling can
be induced by several interleukins (e.g., IL-6) some of which are
known to be up-regulated by IE1 [58,60,61,110]. However,
STAT1 Y701 phosphorylation can also occur independently of
cytokines (reviewed in [134]). In fact, growth factors including the
epidermal growth factor and certain hormones are also able to
induce STAT1 Y701 phosphorylation [135,136,137,138,139]. In
addition, tumor necrosis factor (TNF) has been shown to signal
through activated STAT1 [140] raising the intriguing possibility
that the soluble protein products of TNFSF4 and/or TNFSF18,
two TNF family members belonging to the few genes already
activated by 24 h following IE1 induction (Table 1), may be
involved in IE1-mediated Y701 phosphorylation of STAT1.
However, activation of one or more of these IFN-independent
pathways may not produce enough activated nuclear STAT1 to
trigger efficient ISG expression and may therefore be required but
not sufficient for IE1-mediated gene induction. In accordance with
this possibility, the levels of Y701-phosphorylated STAT1 were
much higher in IFN-c-treated as compared to IE1 expressing cells
(Figure 8 A). Thus, on top of low level Y701 phosphorylation, IE1-
dependent nuclear retention of STAT1 through complex
formation between the viral and cellular protein (as outlined for
the one-step model; see above) may be necessary in order to elicit a
significant transcriptional response (step 2).
Although activated STAT1 is clearly a key mediator of IE1-
dependent ISG induction, additional factors may be involved. In
fact, not all known STAT1-activated human genes seem to be
included in the IE1-specific transcriptome implying that additional
gene products likely contribute to target specificity. One of the
candidate co-factors that has been repeatedly linked to IE1
function is NFkB. In fact, IE1 was shown to activate the NFkB
Figure 10. IE1 increases STAT1 occupancy at ISG promoters. TetR and TetR-IE1 cells were treated with doxycycline for 72 h. During the last
30 min of doxycycline treatment TetR cells were incubated in the presence of solvent, IFN-c or IFN-a. ChIP assays were carried out with polyclonal
rabbit antibodies against STAT1 (A) or STAT2 (B). The fraction of immunoprecipitated DNA relative to input DNA was determined by qPCR with
primers specific for the non-ISGs GAPDH (white circles), ribosomal protein L30 (RPL30) (black circles), and TUBB (gray circles) as well as for the ISGs
GBP4 (white squares), CXCL9 (black squares), TAP1 (gray squares), IFIT2 (white triangles), and OAS1 (black triangles). Mean values of two technical
replicates from TetR-IE1 cells (IE1) and from IFN-c- or IFN-a-treated TetR cells are presented relative to solvent-treated TetR cells (set to 1). Results
from five (A) or two (B) independent experiments are shown.
doi:10.1371/journal.ppat.1002016.g010
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expression of the NFkB RelB subunit and/or NFkB post-
translational activation [58,113,119,121], and to activate transcrip-
tion through NFkB binding sites [58,105,106,113,119,126]. At the
same time, NFkB has been implicated in IFN-c-induced activation
of a subset of ISGs including CXCL10 and GBP2 ([141,142,143,
144,145]; reviewed in [146,147]). However, we did not observe
nuclear translocation of NFkB following induction of IE1 in TetR-
IE1 cells. Moreover, siRNA-mediated knock-down of NFkB p65
had no significant impact on IE1-activated CXCL10 and GBP4
expression in these cells (data not shown). These observations
indicate that the transcriptional response to IE1 is largely
independent of NFkB, at least within our experimental setup.
IRF1 is another transcription factor that contributes to the
activation of certain ISGs including CTSS, GBP2, and TAP1
([128,148,149,150]; reviewed in [80,81,82]). IRF1 might enhance
IE1-mediated ISG activation, especially since its mRNA is up-
regulatedbyexpressionoftheviralprotein (Table 1andFigure4 A).
A key feature of the IE1 protein appears to be its ability to target
to and disrupt subnuclear multi-protein structures known as PML
bodies or ND10 during the early phase of hCMV infection and
upon ectopic expression [42,43,44]. The mechanism of IE1-
dependent ND10 disruption most likely involves binding to the
PML protein, a major constituent of ND10 [54]. We have not
specifically investigated the role of PML in IE1-mediated gene
induction. Nonetheless, our results are compatible with the
possibility that ND10 disruption is required for the transcriptional
response to IE1 since the nuclear structures were confirmed to be
disintegrated at both post-induction time points (24 h and 72 h) of
our microarray analysis (data not shown). Although the exact
function of ND10 remains unclear, the structures have been
implicated in a variety of processes including inflammation [151]
and anti-viral defense (reviewed in [45,46,47,48]). Besides a
proposed role of ND10 in viral gene expression, they may also
function in transcriptional regulation of certain cellular genes.
Several examples of selective associations between ND10 and
genes or chromosomal loci, especially regions of high transcription
activity and/or gene density, have been reported (reviewed in
[152]). For example, immunofluorescent in situ hybridization
analyses demonstrated that the major histocompatibility (MHC)
class I gene cluster on chromosome 6 (6p21) is non-randomly
associated with ND10 in human fibroblasts [153]. Transcriptional
activation in the presence of IFN-c correlates with the relocaliza-
tion of this locus to the exterior of the chromosome 6 territory in a
process that appears to involve DNA binding of Y701-phosphor-
ylated STAT1, changes in chromatin loop architecture, and
histone hyperacetylation [154,155,156]. Interestingly, many IE1-
activated genes cluster in certain genomic locations (Table 2). This
includes the HLA-DRA and TAP1 genes located within the
ND10-associated MHC locus at 6p21. Together these observa-
tions raise the intriguing possibility that, through a combination of
PML disruption and STAT1 activation, IE1 might cause higher
order chromatin remodeling of entire chromosomal loci resulting
in transcriptional activation.
One of the most surprising findings of the present study
concerns the fact that most IE1-induced cellular genes are
generally associated with stimulatory rather than inhibitory effects
on immune function and inflammation (Table 1, Figure 2 and
Supporting Tables S1, S2). It has been proposed that certain
inflammatory and innate defense mechanisms launched by the
host to limit hCMV replication may actually facilitate viral
dissemination, for example by increasing target cell availability
and/or by creating an environment conducive to virus reactivation
(coined ‘‘no pain, no gain’’ by Mocarski [157]). Thus, it is plausible
that hCMV not just attenuates host immunity through the
numerous immune evasion mechanisms ascribed to this virus
(reviewed in [158]), but rather aims at counterbalancing the effects
of the innate and inflammatory response in restricting and
facilitating viral replication. This strategy may be crucial in
allowing for what has been termed ‘‘mutually assured survival’’ of
both virus and host [159].
The functional group of IE1-induced pro-inflammatory proteins
potentially involved in viral target cell recruitment is best
represented by the chemokines CXCL9, CXCL10, and CXCL11.
All three proteins are not only induced by IE1 (Table 1 and
Figures 3–7) but also during hCMV infection of various cell types,
and they represent major constituents of the viral secretome
([4,18,24,160,161,162,163,164,165] and Table 3). By binding to a
common receptor, termed CXCR3, the three chemokines have
the ability to attract subsets of circulating leukocytes to sites of
infection and/or inflammation (reviewed in [74,75]). Although
CXCR3 is preferentially expressed on activated T helper 1 cells,
the receptor protein is also present on many other cell types
including CD34+ hematopoietic progenitors [166] which are
preferential sites of hCMV latency [167,168,169,170,171,172].
Table 3. IE1-activated human genes shown to be induced
during hCMV infection.
Gene
symbol mRNA
1 Protein
2 References
IFI44L + 2 [162]
GBP1 + 2 [12,18,161,224]
GBP2 + 2 [13,15,18,161,224]
GBP4 + 2 This work
3
GBP5 22
CTSS ++ [4,24]
TNFSF18 22
TNFSF4 22
SERTAD4 22
HES1 + 2 [18]
CXCL9 ++ [161,165] and this work
3
CXCL10 ++ [4,18,24,160,161,162,163,164] and this work
3
CXCL11 ++ [4,18,161,162] and this work
3
IRF1 + 2 [12,15,16,17,18,162]
EDN1 22
HLA-DRA + 2 [14]
TAP1 + 2 [14,18,162]
IDO1 + 2 [15,18,161] and this work
3
CD274 22
CCDC3 22
IFIT2 + 2 [12,15,16,18,96,161,162,194,225,226,227,228]
IFIT3 + 2 [15,162,194,224,228]
ANKRD1 22
HBG1 22
CCL11 22
1Up-regulated at the level of mRNA accumulation.
2Up-regulated at the level of protein accumulation and/or secretion.
3Up-regulated at mRNA level by TNwt infection of MRC-5 cells (data not shown).
+=reported to be up-regulated by hCMV; 2=not reported to be up-regulated
by hCMV.
doi:10.1371/journal.ppat.1002016.t003
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inflammatory and immune disorders (reviewed in [74,75]). For
example, cells expressing CXCR3 are found at high numbers in
biopsies taken from patients experiencing organ transplant
dysfunction and/or rejection [173,174,175,176,177,178,179,
180,181]. Moreover, CXCL9 [175,176,177,179,180], CXCL10
[173,174,175,176,177,179,180], and CXCL11 [175,176,177,178,
179,180,181] mRNA and protein levels are increased in tissues of
organs undergoing rejection. Importantly, the levels of CXCR3-
positive cells and CXCR3 ligand mRNA in the biopsy samples
frequently correlate with the grade of graft rejection [174,176,
177,178,180] suggesting a causative role of this pathway. Up-
regulation of CXCL10 and other chemokines also correlated with
transplant vascular sclerosis and chronic rejection in an rCMV
cardiac allograft infection model [4,182,183]. In addition to
CXCL9, CXCL10, and CXCL11, IE1 also up-regulates expres-
sion of CCL11 (Table 1), another CXCR3-interacting chemokine
[184]. Through activation of the CXCR3 axis, IE1 might
contribute to hCMV dissemination and pathogenesis in unex-
pected ways.
The IE1 protein has long been suspected to be a key player in
the events leading to reactivation from hCMV latency although
this view has recently been challenged by functional analysis of the
mCMV and rCMV IE1 orthologs in mouse and rat models of
infection, respectively [37,185]. Nonetheless, inflammatory (in-
cluding allogeneic) immune responses are believed to be efficient
stimuli for hCMV reactivation. In fact, stimulation of latently
infected monocytes or myeloid progenitor cells with pro-
inflammatory cytokines including IFN-c can reactivate viral
replication ([186,187,188,189]; reviewed in [190,191,192]). IFN-
c may aid hCMV reactivation by affecting cellular differentiation
([193]; reviewed in [28,190,191,192]) and/or by activating
transcription through GAS-like elements present in the viral
MIE promoter-enhancer [194]. These GAS-like elements were
shown to be required for efficient hCMV transcription and
replication, at least after low multiplicity infection, and IFNs
enhanced MIE gene expression [194]. Conceivably, the IE1
protein may phenocopy the effect of IFN-c in activating both
cellular ISGs and the viral MIE promoter thereby facilitating viral
reactivation. Conversely, along the lines of the ‘‘immune sensing
hypothesis of latency control’’ proposed by Reddehase and
colleagues [195], episodes of IE1 expression may promote
maintenance of viral latency not only through providing antigenic
peptides (reviewed in [196]) but also by concomitantly activating
critical immune effector functions including antigen transport
(TAP1), processing (CTSS) and presentation (HLA-DRA) as well
as immune cell recruitment (CXCL9, CXCL10, CXCL11,
CCL11; see above) and co-stimulation (TNFSF4, TNFSF18 and
CD274).
Current anti-hCMV strategies are directed against viral DNA
replication, but sometimes fail to halt disease. This may be due to
virus-induced ‘‘side effects’’ that are not correlated to production
of virus particles and lysis of host cells. In fact, in hCMV
pneumonitis and retinitis, disease symptoms were repeatedly found
in the absence of replicating virus or viral cytopathogenicity
[197,198]. Similarly, in mouse models of viral pneumonitis
mCMV replication per se was not sufficient to cause disease
[197,199,200]. Conversely, mCMV disease could be triggered
immunologically without inducing viral replication [201]. Here we
have shown that out of .160 different hCMV gene products, a
single protein (IE1) is sufficient to alter the expression of human
genes with strong pro-inflammatory and immune stimulatory
potential without the requirement for virus replication. The
present work supports the idea that the hCMV MIE gene and
specifically the IE1 protein may play a direct and predominant
role in viral immunopathogenesis and inflammatory disease
[202,203,204,205]. Thus, the IE1 protein should be considered
a prime target for the development of improved prevention and
treatment options directed against hCMV.
Materials and Methods
Plasmids
The pMD2.G and psPAX2 packaging vectors for recombinant
lentivirus production were obtained from Addgene (http://www.
addgene.org; plasmids 12259 and 12260, respectively). Plasmids
pLKOneo.CMV.EGFPnlsTetR, pLKO.DCMV.TetO.cICP0,
and pCMV.TetO.cICP0 were kindly provided by Roger Everett
(Glasgow, UK). pLKOneo.CMV.EGFPnlsTetR contains the
complete hCMV MIE promoter upstream of a sequence encoding
EGFP fused to an NLS and TetR [68,69,70]. In the pLKO.1puro
derivative pLKO.DCMV.TetO.cICP0, expression of the herpes
simplex virus type 1 infected cell protein 0 cDNA (cICP0) is under
the control of a tandem TetO sequence located downstream of a
truncated version of the hCMV MIE promoter (DCMV) [69,70].
To generate pLKO.DCMV.TetO.cIE1, the IE1 cDNA of the
hCMV Towne strain was PCR-amplified from pEGFP-IE1 [71]
with upstream primer #483 containing a HindIII site and
downstream primer #484 containing an EcoRI site (the sequences
of all primers used in this study are listed in Supporting Table S8).
The IE1 sequence was subcloned into the HindIII and EcoRI sites
of pCMV.TetO.cICP0. The NdeI-EcoRI fragment of the resulting
plasmid pCMV.TetO.IE1 was verified by sequencing and used to
replace the ICP0 cDNA in pLKO.DCMV.TetO.cICP0 thereby
generating plasmid pLKO.DCMV.TetO.cIE1.
QuikChange site-directed mutagenesis of plasmid pRc/CMV-
hSTAT1p91 (kindly provided by Christian Schindler, New York,
USA) with oligonucleotides #660 and #661 resulted in pCMV-
STAT1* encoding a STAT1 variant mRNA resistant to silencing
by the STAT1-specific siRNA duplex #146 (the sequences of all
siRNAs used in this study are listed in Supporting Table S9). The
plasmids pCMV-STAT1*Y701F and pCMV-STAT1*S727A
were generated by QuikChange mutagenesis of pCMV-STAT1*
with primer pairs #662/#663 and #664/#665, respectively.
BamHI-EcoRV fragments of pRc/CMV-hSTAT1p91, pCMV-
STAT1*, pCMV-STAT1*Y701F, and pCMV-STAT1*S727A
were treated with Klenow fragment and ligated to the HpaI-
digested, dephosphorylated retroviral vector pLHCX (Clontech,
no. 631511) resulting in plasmids pLHCX-STAT1, pLHCX-
STAT1*, pLHCX-STAT1*Y701F, and pLHCX-STAT1*S727A,
respectively. The correct orientations and nucleotide sequences of
the inserted STAT1 cDNAs were verified by sequencing.
Cells and retroviruses
Human MRC-5 embryonic lung fibroblasts (Sigma-Aldrich,
no. 05011802), the human p53-negative non-small cell lung
carcinoma cell line H1299 (ATCC, no. CRL-5803 [206]), and
Phoenix-Ampho retrovirus packaging cells (from Garry Nolan,
Stanford, USA [207]) were maintained in Dulbecco’s Modified
Eagle’s Medium supplemented with 10% fetal calf serum, 100
units/ml penicillin, and 100 mg/ml streptomycin. All cultures were
regularly screened for mycoplasma contamination using the PCR
Mycoplasma Test Kit II from PromoKine. Where applicable, cells
were treated with 1,000 U/ml recombinant human IFN-a A/D
(R&D Systems, no. 11200), 10 ng/ml recombinant human IFN-b
1a (Biomol, no. 86421), or 10 ng/ml recombinant human IFN-c
(R&D Systems, no. 285-IF) for various durations. Neutralizing
goat antibodies to human IFN-b (no. AF814) or IFN-c (no. AF-
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from R&D Systems and used at concentrations of 1 mg/ml (anti-
IFN-b)o r2mg/ml (anti-IFN-c, normal IgG). Transwell assays
were performed in tissue-culture-treated 100-mm plates with
polycarbonate membrane and 0.4 mm pore size (Corning,
no. 3419).
During the week prior to transfection, Phoenix-Ampho cells were
grown in medium containing hygromycin (300 mg/ml) and diphthe-
ria toxin (1 mg/ml). Production of replication-deficient retroviral
particles, retrovirus infections, and selection of stable cell lines were
performed according to the pLKO.1 protocol available on the
Addgene website (http://www.addgene.org/pgvec1?f=c&cmd=
showcol&colid=170&page=2) with minor modifications. Retroviral
particles were generated by transient transfection of H1299 cells
(pLKO-based vectors) or Phoenix-Ampho cells (pLHCX-based
vectors) using the calcium phosphate co-precipitation technique
[208]. Recombinant viruses were collected 36 h and 60 h after
transfection, and were used for transduction of target cells by two
subsequent 16 h incubations. To generate TetR cells, MRC-5
fibroblasts at population doubling 19 were infected with pLKO-
neo.CMV.EGFPnlsTetR-derived lentiviruses and selected with
G418 (0.2 mg/ml). To generate TetR-IE1 cells, TetR cells were
transduced by pLKO.DCMV.TetO.cIE1-derived lentiviruses and
selected with puromycin (1 mg/ml). Cells with high level EGFPnl-
sTetR expression (and low IE1 background) were enriched by
fluorescence-activated cell sorting in a FACSCanto II flow cytometer
(BD Biosciences). TetR cells were maintained in medium containing
G418 (0.1 mg/ml), while TetR-IE1 cells were cultured in the
presence of both G418 (0.1 mg/ml) and puromycin (0.5 mg/ml). To
induce IE1 expression, cells were treated with doxycycline (Clontech,
no. 631311) at a final concentration of 1 mg/ml. To generate TetR-
IE1 cells with stable expression of ectopic STAT1 proteins,
uninduced TetR-IE1 cells were transduced with pLHCX-derived
retroviruses encoding STAT1, STAT1*, STAT1*Y701F, or
STAT1*S727A.
hCMV mutagenesis and infection
The EGFP-expressing wild-type Towne strain (TNwt) of hCMV
was derived from an infectious BAC clone (T-BACwt [209]) of the
viral genome. Allelic exchange to generate IE1-deficient viruses
(TNdlIE1) and corresponding ‘‘revertants’’ (TNrvIE1) utilized the
following derivatives of transfer plasmid pGS284 [210]: pGS284-
TNIE1kanlacZ, pGS284-TNMIEdlIE1, pGS248-TNMIE, and
pGS284-TNMIErvIE1. Plasmid pGS284-TNIE1kanlacZ contains
the kanamycin resistance gene (kan) and the lacZ gene cloned
between sequences flanking the IE1-specific exon four of the
hCMV TN MIE transcription unit. The ,1000-bp flanking
sequences were obtained by PCR amplification using primers
#136 and #137 (downstream flanking sequence) or #139 and
#140 (upstream flanking sequence; for PCR primer sequences, see
Supporting Table S8) and T-BACwt as template. The amplified
downstream flanking sequence was cloned into pGS284 via BglII
and NotI sites present in both the PCR primers and target vector
sequences. Following addition of adenosine nucleotide overhangs
to the 39-ends of the PCR product, the upstream flanking sequence
was first subcloned into vector pCR4-TOPO (Invitrogen) and
subsequently inserted via NotI sites into pGS284 carrying the
downstream flanking sequence. The kanlacZ expression cassette
was released from plasmid YD-C54 [211] and cloned into the PacI
sites (introduced through PCR primers #137 and #139) located
between the hCMV flanking sequences in the pGS284 derivative
described above. Plasmid pGS284-TNMIEdlIE1 contains an MIE
fragment lacking 1,413 bp between the AccI sites upstream and
downstream of exon four. The exon four-deleted MIE fragment
was obtained from T-BACwt by overlap extension PCR as
previously described [212]. The primer pairs used for PCR
mutagenesis were #348/#349 (upstream fragment), #350/#351
(downstream fragment), and #348/#351 (complete fragment).
The final PCR product was cloned via BglII and NotI sites into
pGS284. For the construction of pGS248-TNMIE (previously
termed pGS248-MIE; [33]), a ,3000-bp sequence of the MIE
region was amplified by PCR using template T-BACwt and
primers #155 and #156. After phosphorylation, the PCR product
was first inserted into the SmaI site of pUC18 and then excised
from this vector via FseI and NotI sites. The FseI-NotI fragment was
subsequently cloned into the same sites of pGS284-TNMIEdlIE1
thereby repairing the exon four deletion in this plasmid to generate
pGS284-TNMIErvIE1. DNA sequence analysis was completed on
all hCMV-specific PCR amplification products to confirm their
integrity. Allelic exchange was performed through homologous
recombination in Escherichia coli strain GS500 as previously
described [33,210,211]. First, the BAC pTNIE1kanlacZ was
generated by recombination of T-BACwt with pGS284-TNIE1-
kanlacZ followed by selection for kanamycin resistance and LacZ
expression. After that, the BACs pTNdlIE1 and pTNrvIE1 were
made through recombination of pTNIE1kanlacZ with pGS284-
TNMIEdlIE1 and pGS284-TNMIErvIE1, respectively, followed
by selection for the loss of kanamycin resistance and LacZ
expression. The BAC constructs were analyzed by EcoRI digestion.
The BACs pTNdlIE1 and pTNrvIE1 were used for electroporation
of MRC-5 cells to reconstitute viruses TNdlIE1 and TNrvIE1,
respectively, as has been described previously [211]. Cell- and
serum-free virus stocks were produced upon BAC transfection of
MRC-5 fibroblasts (TNwt and TNrvIE1) or TetR-IE1 cells
(TNdlIE1), and the titers of the wild-type TN and revertant
preparations were determined by standard plaque assay on MRC-
5 cells. Titration of TNdlIE1 stocks was performed by quantifi-
cation of intracellular genome equivalents [33]. Multistep
replication analysis of recombinant viruses on TetR and TetR-
IE1 cells has been described previously [33].
GeneChip analysis
For global transcriptome analysis, 1.9610
6 TetR or TetR-IE1
cells of the same passage number were seeded on 10-cm dishes.
When cells reached confluency (three days after plating), the
medium was replaced, and cells were growth-arrested by
maintaining them in the same medium for seven days before they
were collected for transcriptome analysis. During the last 72 h or
24 h prior to collection, cultures were treated with doxycycline at a
final concentration of 1 mg/ml or were left untreated. Total RNA
was isolated using TRIzol reagent (Invitrogen) and Phase Lock Gel
Heavy (Eppendorf) according to the manufacturers’ instructions. A
second purification step with on-column DNase digestion was
performed on the isolated RNA using the RNeasy Mini Kit from
Qiagen. All subsequent steps were performed at the Kompetenz-
zentrum fu ¨r Fluoreszente Bioanalytik (Regensburg, Germany).
Total RNA (100 ng) was labeled using reagents and protocols
specified in the Affymetrix GeneChip Whole Transcript (WT)
Sense Target Labeling Assay Manual (P/N 701880 Rev. 4).
Quantity and quality of starting total RNA, cRNA, and single-
stranded cDNA were assessed in a NanoDrop spectrophotometer
(Thermo Fisher Scientific) and a 2100 Bioanalyzer (Agilent
Technologies), respectively. Samples were hybridized to Affyme-
trix Human Gene 1.0 ST Arrays which interrogate 28,869 well-
annotated genes and cover .99% of sequences present in the
RefSeq database (National Center for Biotechnology Information).
We probed a total of 18 microarrays, which allowed us to monitor
three biological replicates for each experimental condition (TetR
HCMV IE1 Elicits IFN-c-Like Response
PLoS Pathogens | www.plospathogens.org 17 April 2011 | Volume 7 | Issue 4 | e1002016and TetR-IE1 cells without and with 24 h and 72 h of doxycycline
treatment). For creation of the summarized probe intensity signals,
the Robust Multi-Array Average algorithm [213] was used. Files
generated by the Affymetrix GeneChip Operating 1.4 and
Expression Console 1.1 software have been deposited in Gene
Expression Omnibus (GEO, National Center for Biotechnology
Information [214]) and are accessible through GEO Series
accession number GSE24434 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE24434).
qRT-PCR
In order to determine steady-state mRNA levels by qRT-PCR,
total RNA was isolated from 3 to 4610
5 fibroblasts using
Qiagen’s RNeasy Mini Kit and RNase-Free DNase Set according
to the manufacturer’s instructions. First-strand cDNA was
synthesized using SuperScript III and Oligo(dT)20 primers
(Invitrogen) starting from 2 mg of total RNA. Unless otherwise
noted, first-strand cDNA was diluted 10-fold with sterile
ultrapure water, and 5 ml were used to template 20-mlr e a l - t i m e
PCRs performed in a Roche LightCycler 1.5 [33]. The
instrument was operated with a ramp rate of 20uCp e rs e cu s i n g
the following protocol: pre-incubation cycle (95uC for 10 min,
analysis mode: none), 40 to 50 amplification cycles with single
fluorescence measurement at the end of the extension step
(denaturation at 95uC for 10 sec, primer-dependent annealing at
66 to 56uC for 10 sec, primer-dependent extension at 72uC for 8
to 10 sec, analysis mode: quantification), melting curve cycle with
continuous data acquisition during the melting step (denaturation
at 95uC for 0 sec, annealing at 65uC for 60 sec, melting at 95uC
for 0 sec with a ramp rate of 0.1uC/sec, analysis mode: melting
curves), cooling cycle (40uC for 30 sec, analysis mode: none). The
PCR mix was composed of 9 ml PCR grade water, 1 ml forward
primer solution (10 mM), 1 ml reverse primer solution (10 mM),
and 4 ml5 6 concentrated Master Mix from the LightCycler
FastStart DNA Master
PLUS SYBR Green I kit. The sequences of
the high pressure liquid chromatography-purified PCR primers
are listed in Supporting Table S8. All samples were quantified at
least in duplicate, and each analysis included positive, minus-RT,
and non-templated controls. The second derivate maximum
method with arithmetic baseline adjustment (LightCycler Soft-
ware 3.5) was used to determine quantification cycle (Cq) values.
Cq values were further validated by ensuring they meet the
following criteria: (i) corresponding melting peaks of the
generated PCR products, calculated using the polynomial
method with digital filters enabled, had to match the single peak
of the positive control sample, (ii) standard deviations of Cq
values from technical replicates had to be below 0.33, (iii) Cq
values had to be significantly different from minus-RT controls
(CqƒCq-RT-1), and (iv) Cq values had to be within the linear
quantification range. The linear quantification range was
individually determined for each primer pair by generating a
standard curve with serial dilutions of first-strand cDNA from the
sample with the highest expression level. PCR efficiency (E)w a s
calculated from the slope of the standard curve according to
equation (1):
E~10
{1
slope

ð1Þ
The relative expression ratio (R) of the target (trgt) and reference
(ref) gene in an experimental (eptl) versus control (ctrl) sample was
calculated using the efficiency-corrected model shown in equation
(2):
R~
Etrgt
Cqtrgt ctrl ðÞ {Cqtrgt eptl ðÞ ðÞ
Eref
(Cqref ctrl ðÞ {Cqref eptl ðÞ )
ð2Þ
Control samples of all experiments had reference and target
gene expression levels well above the limits of detection. The
tubulin-b gene (TUBB) was chosen as a reference, because (i)
expression levels did not change upon IE1 induction, IFN
treatment, siRNA transfection, or hCMV infection, (ii) it allowed
for RNA-specific detection with no spurious product generation in
minus-RT controls, and (iii) it exhibited similar expression levels
compared to the target genes under investigation, which were
generally expressed at levels lower than TUBB in the absence and
at similar or higher levels relative to TUBB in the presence of IE1
expression, IFN treatment, or hCMV infection.
Chemokine quantification
CXCL9, CXCL10, and CXCL11 chemokine concentrations in
cell culture supernatants were determined using commercially
available colorimetric sandwich enzyme immunoassay kits (Quan-
tikine Immunoassays no. DCX900, DIP100, and DCX110 from
R&D Systems) following the manufacturer’s instructions.
RNA interference
The sequences of siRNA duplexes used for mRNA knock-down
experiments are listed in Supporting Table S9. They were
introduced into cells at 30 nM final concentration using the
Lipofectamine RNAiMAX Reagent (Invitrogen) following the
manufacturer’s instructions. Briefly, exponentially growing cells
were seeded either in 12-well dishes at 2.5610
5 cells/well for RNA
analyses or in 6-well dishes at 5610
5 cells/well for protein
analyses. Transfections were performed in Opti-MEM I Reduced
Serum Medium (Invitrogen) with 2 mlo r5 ml of RNAiMAX
Reagent for 12- or 6-wells, respectively.
Subcellular fractionation, immunoblotting, and
microscopy
Cells (3.8610
6) on 10-cm dishes were collected with trypsin/
EDTA and then centrifuged for 5 min at 5006 g and 4uC.
Supernatants were removed and cells resuspended in 100 ml CSK
buffer (10 mM PIPES [pH 6.8], 300 mM sucrose, 100 mM NaCl,
3 mM MgCl2, 1 mM EDTA, 0.1% (v/v) Igepal CA-630) with
freshly added protease and phosphatase inhibitor cocktails. Lysates
were centrifuged for 1 min at 1,3006 g and 4uC, and the
supernatants (cytoplasmic extracts) were transferred to clean pre-
chilled tubes and combined with one volume of 26protein sample
buffer (100 mM Tris-HCl [pH 6.8], 4% (w/v) SDS, 20% (v/v)
glycerol, 200 mM b-mercaptoethanol, 0.1% (w/v) bromophenol
blue). The insoluble (pellet) fractions containing nuclei were
washed once with 500 ml CSK buffer before they were suspended
in 200 ml2 6 protein sample buffer and sonified in a Bioruptor
(Diagenode; ‘‘H’’ setting; 30 sec on-off interval) for 15 min.
Samples were centrifuged for 10 min at 20,0006g and 4uC, and
the supernatants (nuclear extracts) were transferred to clean pre-
chilled tubes. Cytosolic and nuclear extracts were heated to 95uC
for 5 min before immunoblot analysis. Generation of whole cell
extracts, sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis, immunoblotting, and (immuno)fluorescence microscopy were
performed according to previously published protocols [33,
53,215]. Immunodetection employed primary mono- or polyclon-
al antibodies directed against hCMV IE1 (1B12; [216]) or human
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no. ab13923), STAT1 (no. sc-464 for immunoblotting and
no. sc-346 for immunofluorescence, both from Santa Cruz),
STAT1a (Santa Cruz, no. sc-345), STAT2 (Santa Cruz, no. sc-
22816), and phosphorylated STAT1 (Y701-specific antibody
no. 9171 and S727-specific antibody no. 9177, both from Cell
Signaling Technologies). The secondary antibodies used were
peroxidase-conjugated goat anti-mouse (no. 115-035-166) or goat
anti-rabbit IgG (no. 111-035-144) from Dianova for immunoblot-
ting, and highly cross-adsorbed Alexa Fluor 594- or Alexa Fluor
633-conjugated goat anti-mouse (no. A-11032 or no. A-21052,
respectively) and Alexa Fluor 546-conjugated goat anti-rabbit IgG
(no. A-11035) from Invitrogen for immunofluorescence.
ChIP assay
ChIP was performed essentially as described by Nelson et al.
[217,218]. Resting cells on a 15-cm dish were cross-linked by
treatment with 1% (v/v) formaldehyde for 10 min at 37uC.
Isolated chromatin was sonified for 15 min in a Bioruptor
(Diagenode; ‘‘H’’ setting, 30 sec on-off interval) and cleared by
centrifugation for 20 min at 20,0006 g and 4uC. Sheared
chromatin from 7610
6 cells (0.7 ml) was subjected to immuno-
precipitation for 16 h at 4uC with gentle rotation using 10 mgo f
antibody. Two different polyclonal rabbit antibodies each against
STAT1 (no. sc-3454 and sc-346 from Santa Cruz) and STAT2
(no. sc-476 and sc-839 from Santa Cruz) were used. After the
antibody incubation step, insoluble material was removed by
centrifugation (10 min at 20,0006g and 4uC) and 0.63 ml (90%)
supernatant was transferred to a clean pre-chilled tube. Antibody-
antigen complexes were isolated by sedimentation following
incubation with 60 ml of Protein A Agarose/Salmon Sperm
DNA slurry (Millipore) for 60 min at 4uC. PCR-ready DNA was
prepared using Chelex-100 and duplicate samples of 5 ml (25% of
the final reaction volume) each were used for DNA quantification
by qPCR as described above and in recent publications [33,215].
The PCR primer sequences are listed in Supporting Table S8.
Supporting Information
Figure S1 Time course qRT-PCR analysis of IFN-b and IFN-c
expression. TetR and TetR-IE1 cells were treated with doxycy-
cline for 3 to 96 h or were left untreated (0 h). Relative mRNA
expression levels were determined from 5 ml of undiluted cDNA
by qRT-PCR with primers specific for the IFNB and IFNG genes.
Results were normalized to TUBB, and means of two biological
replicates are shown in comparison to untreated cells (set to 1).
(EPS)
Figure S2 STAT2 knock-down is functionally effective and can
down-regulate a bona fide STAT2-responsive gene. MRC-5 cells
were transfected with control siRNA #149 or STAT2-specific
siRNA #152. Four days post transfection cells were treated with
IFN-a (10 ng/ml) for 24 h or were left untreated (w/o). Relative
mRNA expression levels were determined by qRT-PCR with
primers specific for the type I ISGs STAT2 and OAS1. Results
were normalized to TUBB and mean values with standard
deviations from two biological and two technical replicates are
shown. Expression is presented relative to control siRNA-
transfected cells without IFN-a stimulation (set to 1).
(EPS)
Table S1 Enrichment of GO ‘‘biological process’’
(GO:0008150) terms (p,0.2) in IE1-activated genes.
(DOC)
Table S2 Enrichment of GO ‘‘molecular function’’
(GO:0003674) terms (p,0.2) in IE1-activated genes.
(DOC)
Table S3 Enrichment of GO ‘‘cellular component’’
(GO:0005575) terms (p,10) in IE1-activated genes.
(DOC)
Table S4 qRT-PCR analysis of IFN responsiveness of IE1-
induced genes.
(DOC)
Table S5 Results of GeneChip analysis for IFN genes.
(DOC)
Table S6 qRT-PCR analysis of IFN-b and IFN-c expression.
(DOC)
Table S7 STAT1 binding sites in the promoter regions of IE1-
activated human genes.
(DOC)
Table S8 Oligonucleotides used in this study.
(DOC)
Table S9 siRNAs used in this study.
(DOC)
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